Diário da Constituinte [gravação de vídeo] : [programa n. 414]

Constituinte termina a votação do 1º Título. A apreciação dos direitos individuais e coletivos, ficaram para a próxima semana. Os líderes aproveitam para tentar o acordo sobre o Título 2. Os constituintes só esperam a hora para defender no Plenário as suas emendas. As propostas vão do monopólio do petróleo ao controle da propaganda. A supressão do artigo que estatiza a distribuição dos derivados de petróleo é uma das propostas. A expectativa é de que o Plenário trabalhe com agilidade para terminar o mais rapidamente a Constituição. O repúdio à discriminação sexual não vai ficar explícito na nova Carta. Foi aprovada a formação de uma comunidade Latino-Americana, para facilitar a integração com os demais países da América Latina.

Determination of the activity of nitrifying bacteria in surface waters by a modified BOD-test. [Translation from: Zentbl.Bakt.Parasitkde 156(1) 414-421, 1972. ]

A modified method of the Biochemical oxygen demand (BOD)test was applied in order to find out the seasonal changing activity of the nitrifying bacteria in surface waters. Samples were taken from the River Elbe near Teufelsbrueck.

The prognosis of incurable cachectic cancer patients on home parenteral nutrition: A multi-centre observational study with prospective follow-up of 414 patients

Background: The role of home parenteral nutrition (HPN) in incurable cachectic cancer patients unable to eat is extremely controversial. The aim of this study is to analyse which factors can influence the outcome. Patients and methods: We studied prospectively 414 incurable cachectic (sub)obstructed cancer patients receiving HPN and analysed the association between patient or clinical characteristics and surviving status. Results: Median weight loss, versus pre-disease and last 6-month period, was 24% and 16%, respectively. Median body mass index was 19.5, median KPS was 60, median life expectancy was 3 months. Mean/median survival was 4.7/3.0 months; 50.0% and 22.9% of patients survived 3 and 6 months, respectively. At the multivariable analysis, the variables significantly associated with 3- and 6-month survival were Glasgow Prognostic Score (GPS) and KPS, and GPS, KPS and tumour spread, respectively. By the aggregation of the significant variables, it was possible to dissect several classes of patients with different survival probabilities. Conclusions: The outcome of cachectic incurable cancer patients on HPN is not homogeneous. It is possible to identify groups of patients with a ≥6-month survival (possibly longer than that allowed in starvation). The indications for HPN can be modulated on these clinical/biochemical indices. © The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.

Y-90-Ibritumomab Tiuxetan (Zevalin (R)) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin's Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients

The FIT trial was conducted to evaluate the safety and efficacy of 90Y-ibritumomab tiuxetan (0.4 mCi/kg; maximum dose 32 mCi) when used as consolidation of first complete or partial remission in patients with previously untreated, advanced-stage follicular lymphoma (FL). Patients were randomly assigned to either 90Y-ibritumomab treatment (n = 207) or observation (n = 202) within 3 months (mo) of completing initial induction therapy (chemotherapy only: 86%; rituximab in combination with chemotherapy: 14%). Response status prior to randomization did not differ between the groups: 52% complete response (CR)/CR unconfirmed (CRu) to induction therapy and 48% partial response (PR) in the 90Y-ibritumomab arm vs 53% CR/CRu and 44% PR in the control arm. The primary endpoint was progression-free survival (PFS) of the intent-to-treat (ITT) population. Results from the first extended follow-up after a median of 3.5 years revealed a significant improvement in PFS from the time of randomization with 90Y-ibritumomab consolidation compared with control (36.5 vs 13.3 mo, respectively; P < 0.0001; Morschhauser et al. JCO. 2008; 26:5156-5164). Here we report a median follow-up of 66.2 mo (5.5 years). Five-year PFS was 47% in the 90Y-ibritumomab group and 29% in the control group (hazard ratio (HR) = 0.51, 95% CI 0.39-0.65; P < 0.0001). Median PFS in the 90Y-ibritumomab group was 49 mo vs 14 mo in the control group. In patients achieving a CR/CRu after induction, 5-year PFS was 57% in the 90Y-ibritumomab group, and the median had not yet been reached at 92 months, compared with a 43% 5-year PFS in the control group and a median of 31 mo (HR = 0.61, 95% CI 0.42-0.89). For patients in PR after induction, the 5-year PFS was 38% in the 90Y-ibritumomab group with a median PFS of 30 mo vs 14% in the control group with a median PFS of 6 mo (HR = 0.38, 95% CI 0.27-0.53). Patients who had received rituximab as part of induction treatment had a 5-year PFS of 64% in the 90Y-ibritumomab group and 48% in the control group (HR = 0.66, 95% CI 0.30-1.47). For all patients, time to next treatment (as calculated from the date of randomization) differed significantly between both groups; median not reached at 99 mo in the 90Y-ibritumomab group vs 35 mo in the control group (P < 0.0001). The majority of patients received rituximab-containing regimens when treated after progression (63/82 [77%] in the 90Y-ibritumomab group and 102/122 [84%] in the control group). Overall response rate to second-line treatment was 79% in the 90Y-ibritumomab group (57% CR/CRu and 22% PR) vs 78% in the control arm (59% CR/CRu, 19% PR). Five-year overall survival was not significantly different between the groups; 93% and 89% in the 90Y-ibritumomab and control groups, respectively (P = 0.561). To date, 40 patients have died; 18 in the 90Y-ibritumomab group and 22 in the control group. Secondary malignancies were diagnosed in 16 patients in the 90Y-ibritumomab arm vs 9 patients in the control arm (P = 0.19). There were 6 (3%) cases of myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) in the 90Y-ibritumomab arm vs 1 MDS in the control arm (P = 0.063). In conclusion, this extended follow-up of the FIT trial confirms the benefit of 90Y-ibritumomab consolidation with a nearly 3 year advantage in median PFS. A significant 5-year PFS improvement was confirmed for patients with a CR/CRu or a PR after induction. Effective rescue treatment with rituximab-containing regimens may explain the observed no difference in overall survival between both patient groups who were - for the greater part - rituximab-naïve.

Les diplômés – no 414, printemps 2008

Pour toute demande de reproduction de contenu se trouvant dans cette publication, communiquer avec l’Association des diplômés de l’UdeM.

CC98-414 Money 2000+ Setting a Goal

Money 2000+ provides you with opportunities to acquire skills and information to help you reach your money goal(s). The first step with Money 2000+ is setting your goal(s). Then, by taking more control of your spending and where your money goes, you may be surprised at what you can actually accomplish as you progress with Money 2000+ Maybe you already know what you want to accomplish. Even so, take some time to read the rest of this booklet and to think about all parts of your life to make sure you don't miss something important.

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 414 - Gedicht auf Christian Friedrich Schulze "Der Kanzel Zierde"

1 Blatt

Ms.Ff.F.Stoltze 3. 414 - Brief von Friedrich Stoltze an Adolf Stoltze

Familienstreitigkeiten, Die Großmutter, Marie Stoltze, Adolfs Namensprobleme

Na 1 Nachlass Max Horkheimer, 546 - Korrespondenzen mit Leo Löwenthal (p. VI 18, 215-414)

135 Briefe zwischen Leo Löwenthal und Max Horkheimer; 2 Briefe von Max Horkheimer an S. Flowerman, 1945/1946; 2 Briefe zwischen John Slawson und Max Horkheimer, Februar 1946; 1 Brief von R. Nevitt Sanford an John Slawson, 31.01.1946; 1 Brief von Paul Lazarsfeld an Norbert K. Merton, 04.02.1946; 1 Brief von Paul Lazarsfeld an Theodore Abel, 05.02.1946; 2 Briefe zwischen Max Horkheimer und Dessie E. Kushell, Januar 1946; 3 Briefe von Max Horkheimer an Margaret Nicolson, Januar 1946;

Acta acuerdo de cooperación entre la Facultad de Humanidades y Ciencias Sociales de la Universidad Nacional de Misiones y la Facultad de Humanidades de la Universidad Nacional del Nordeste. Resolución n° 414

Convenio Específico, en el marco del Convenio de Cooperación Universidades Nacionales del Norte Grande Argentino (Resolución CS N° 024/03) para la realización de actividades conjuntas entre FHyCS-UNaM y "FH-UNNE", en las áreas de Ciencias de la Información y de Tecnologías informáticas aplicadas a la Documentación.

Samaja, Juan. Epistemología y metodología. Elementos para una teoría de la investigación científica. 3ª edición, 6ª reimpresión. Buenos Aires, EUDEBA, 2005, 414 p.

Fil: Fischetti, Natalia.